All articles by GlobalData Healthcare

  1. AstraZeneca’s Imfinzi looks to maintenance setting in advanced NSCLC to reverse fortunes

    Since the disappointment of the Phase III MYSTIC trial failure earlier this year, AstraZeneca has redirected its efforts in non-small…
    Read More…

    20 Oct
  2. Spyryx begins enrolment in Phase II cystic fibrosis trial of SPX-101

    US-based biopharmaceutical firm Spyryx Biosciences has started patient enrolment in a Phase II clinical trial (HOPE-1) of its investigational candidate…
    Read More…

    20 Oct
  3. BioLineRx launches Phase Ib/II combination trial of BL-8040 for gastric cancer

    Israeli biopharmaceutical firm BioLineRx and Genentech have launched a Phase Ib/II clinical trial of BL-8040 and atezolizumab (Tecentriq) in patients…
    Read More…

    20 Oct
  4. Acticor Biotech to assess ACT017 in Phase I trial

    French biotechnology firm Acticor Biotech has entered an agreement to study Dutch Authorities’ investigational drug candidate ACT017 in a Phase…
    Read More…

    19 Oct
  5. Tenapanor likely to makes waves in IBS-C space

    On 11 October, Ardelyx reported positive results from a second pivotal Phase III trial (T3MPO-2) assessing the efficacy and safety…
    Read More…

    18 Oct
  6. Women make up more than 70% of Alzheimer’s disease prevalent cases

    Alzheimer’s disease (AD) is a subtype of dementia and is an irreversible neurodegenerative brain disease of the elderly, characterised by…
    Read More…

    18 Oct
  7. Chi-Med and AstraZeneca report data of savolitinib in two Phase Ib/II trials for NSCLC

    Hutchison China MediTech and AstraZeneca have reported positive preliminary safety and clinical activity results of savolitinib from two Phase Ib/II…
    Read More…

    18 Oct
  8. Sanofi and Regeneron report positive Phase II data of dupilumab for oesophagitis

    Sanofi and Regeneron have reported positive results from a Phase II clinical trial of dupilumab for the treatment of adults…
    Read More…

    18 Oct
  9. Anacetrapib failure marks the death of the CETP class of cholesterol-lowering therapies

    Merck & Co recently decided not to apply for regulatory approval of anacetrapib, one of the last-standing drugs from the…
    Read More…

    17 Oct
  10. Melanoma to significantly increase in the adult US population

    The burden of melanoma of the skin is expected to grow in men and women, ages 18 years and older…
    Read More…

    17 Oct